Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024
“Cognitive functioning is an underappreciated facet of sleep disorders.
- “Cognitive functioning is an underappreciated facet of sleep disorders.
- Often overshadowed by clinically defining symptoms such as EDS, impaired cognition involves significant burden to patient lives.
- The SHARP study of solriamfetol showed improved cognitive functioning in participants with impaired cognition associated with OSA and EDS,” said Hans Van Dongen, PhD, Professor at Washington State University and presenting author of the SHARP study plenary lecture.
- Poster Date/Time: Wednesday, June 5 from 11-11:45 a.m. Central Time
Title: SURWEY: Treatment of Excessive Daytime Sleepiness with Solriamfetol: Initiation, Titration, and Outcomes